Results 81 to 90 of about 5,967 (167)

A Case of Primary Intramedullary Infantile Fibrosarcoma With an RBPMS::NTRK3 Fusion and Response to Larotrectinib

Neuropathology and Applied Neurobiology, Volume 52, Issue 5, October 2026.
We report a case of primary intramedullary infantile fibrosarcoma (IFS) in a 4‐week‐old infant with rapidly progressive cervical myelopathy. Histology showed a spindle cell tumour with diffuse S100 and pan‐TRK expression. RNA sequencing identified an RBPMS::NTRK3 fusion.
Mégane Le Quang, Julie Tandonnet, Nathalène Truffaux, Lucile Vanhersecke, Jean Delmas, Arthur Durouchoux, Dorian Bochaton, Arnault Tauziède‐Espariat, Guillaume Chotard   +8 more
wiley   +1 more source

Challenges in the Diagnosis of NTRK Fusion-Positive Cancers [PDF]

Journal of Thoracic Oncology, 2020
Gautschi O, Bubendorf L, Leyvraz S, Menon R, Diebold J   +4 more
openaire   +3 more sources

RNA hybrid-capture next-generation sequencing has high sensitivity in identifying known and less characterized oncogenic and likely oncogenic NTRK fusions in a real-world standard-of-care setting

Frontiers in Genetics
IntroductionNTRK1, NTRK2, and NTRK3 gene fusions are rare oncogenic driver alterations found in diverse tumor types of adults and children. They are clinically important biomarkers as tumors harboring these genomic alterations have high response rates to
Zachary D. Wallen, Marni Tierno, Erica Schnettler, Alison Roos, Michelle Green, Kobina Amoah, Rebecca A. Previs, Stephanie Hastings, Sarabjot Pabla, Taylor J. Jensen, Brian Caveney, Marcia Eisenberg, Pratheesh Sathyan, Shakti H. Ramkissoon, Shakti H. Ramkissoon, Eric A. Severson   +15 more
doaj   +1 more source

Characterization of Ntrk fusions and Therapeutic Response to Ntrk Inhibition in Hematologic Malignancies

Blood, 2017
Abstract Chromosomal rearrangements involving the neurotrophic receptor tyrosine kinases NTRK1-3 produce oncogenic fusions in a wide variety of adult and pediatric cancers. Although the frequency of NTRK fusions in most cancers is <5%, efficacy in solid tumors harboring these fusions is striking with a 76% durable response rate ...
Justin Taylor, Christina Marcelus, Dean Pavlick, Ryma Benayed, Akihide Yoshimi, Emiliano Cocco, Benjamin H Durham, Jaclyn F Hechtman, Young Rock Chung, Kerry Mullaney, Justin M Watts, Eli L Diamond, Lee A Albacker, Tariq I Mughal, Kevin Ebata, Brian B. Tuch, Nora Ku, Maurizio Scaltriti, Maria E. Arcila, Siraj M Ali, David M. Hyman, Omar Abdel-Wahab, Jae H. Park   +22 more
openaire   +1 more source

NTRK-rearranged spindle cell tumor with SPECC1L-NTRK3 fusion in the thoracic spine: a case report

Journal of Cancer Research and Clinical Oncology
Neurotrophic Tyrosine Receptor Kinase (NTRK)-rearranged spindle cell tumors are a category of soft tissue tumors characterized by rearrangements of the NTRK gene family (NTRK1, NTRK2, and NTRK3), which leads to distinct molecular genetics, morphological,
Mi Zhou, Huaiyuan Xu, Jianxiong Niu, Qibing Yang, Anqi Wang, Hao Wu, Xiangqin Wang, Meng Yang, Jinxin Hu, Qinglian Tang, Jin Wang   +10 more
doaj   +1 more source

From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis

Frontiers in Pharmacology
Introduction: The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions has facilitated the development of precision oncology. Two first-generation NTRK inhibitors (larotrectinib and entrectinib) are currently approved for the treatment ...
Zhiwei Cui, Zhen Zhai, De Xie, Lihui Wang, Feiyan Cheng, Siyu Lou, Fan Zou, Rumeng Pan, Shixue Chang, Haoyan Yao, Jing She, Yidan Zhang, Xinyuan Yang   +12 more
doaj   +1 more source

Neurotrophic tyrosine receptor kinase gene fusions in adult and pediatric patients with solid tumors: a clinicogenomic biobank and record linkage study of expression frequency and patient characteristics from Finland

Acta Oncologica
Background: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers. Using the Auria Biobank in Finland, we aimed to identify and characterize patients with these gene fusions, and describe their clinical and tumor ...
Wei Zhang, Arndt A. Schmitz, Roosa E. Kallionpää, Merja Perälä, Niina Pitkänen, Mikko Tukiainen, Erika Alanne, Korinna Jöhrens, Renate Schulze-Rath, Bahman Farahmand, Jihong Zong   +10 more
doaj   +1 more source

High prevalence of NTRK fusions in sporadic dMMR/MSI mCRC RAS/RAF wild-type: an opportunity for a post-immune checkpoint inhibitors progression rescue strategy

ESMO Gastrointestinal Oncology
Background: Currently, mismatch repair deficient/microsatellite instable (dMMR/MSI) status constitutes a validated predictive marker of response to immune checkpoint inhibitors (ICIs) in patients with metastatic colorectal cancer (mCRC).
M. Svrcek, A. Cayre, T. Samaille, R. Colle, L. Mas, P. Bourgoin, E. Guillerm, R. Cohen, F. Penault-Llorca, T. André, N. Radosevic-Robin   +10 more
doaj   +1 more source

NTRK-rearranged spindle cell neoplasm of the female genital tract: case report and literature review

Frontiers in Oncology
NTRK-rearranged spindle cell neoplasm is a rare subtype of soft tissue sarcoma that occasionally arises in the lower female genital tract. Accurate diagnosis is clinically important, as these tumors generally display low-grade malignant behavior and may ...
Lulu Feng, Lulu Feng, Lei Li, Lei Li, Yanmei He, Yanmei He, Wei Jiang, Wei Jiang   +7 more
doaj   +1 more source

How I treat NTRK gene fusion-positive cancers

ESMO Open, 2019
NTRK fusions are found at low frequencies (commonly
openaire   +5 more sources